Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod immunological response study in relapsing-remitting multiple sclerosis
2016-000708-26Phase 4Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Policlinico Gemelli. Primary endpoint: Change in Treg/Teffector ratio during fingolimod treatment. Started Jun 2021; status: terminated.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on 2016-000708-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000708-26.